None
Quote | Brent Resources Group Ltd (OTCMKTS:BRRGF)
Last: | $0.025 |
---|---|
Change Percent: | 0.0% |
Open: | $0.025 |
Close: | $0.025 |
High: | $0.025 |
Low: | $0.025 |
Volume: | 37,305 |
Last Trade Date Time: | 11/29/2023 03:00:00 am |
News | Brent Resources Group Ltd (OTCMKTS:BRRGF)
2024-07-24 03:06:53 ET Summary Rigel Pharmaceuticals focuses on innovative therapeutics for hematological conditions and cancers, with FDA-approved products Tavalisse, Rezlidhia, and Gavreto targeting specific diseases. RIGL’s pipeline also includes promising drug candidate...
BerGenBio press release ( OTCPK:BRRGF ): Q4 Revenue of NOK0.4M. Cash and cash equivalents of NOK150.8M For further details see: BerGenBio reports Q4 results
Message Board Posts | Brent Resources Group Ltd (OTCMKTS:BRRGF)
Subject | By | Source | When |
---|---|---|---|
BRRGF BGBIO | Fezziwig2008 | investorshub | 07/23/2020 11:30:30 AM |
Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma | Fezziwig2008 | investorshub | 07/20/2020 11:54:48 AM |
BGBIO $BRRGF Sharply Up on a Red day | Fezziwig2008 | investorshub | 07/16/2020 9:42:59 AM |
BergenBio Bemcentinib # 1 Drug in U.K. COVID19 | Fezziwig2008 | investorshub | 07/12/2020 9:11:43 PM |
News, Short Squeeze, Breakout and More Instantly...
Brent Resources Group Ltd Company Name:
BRRGF Stock Symbol:
OTCMKTS Market:
Brent Resources Group Ltd Website:
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients PR Newswire BERGEN, Norway ...
BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 BERGEN, Norway , Dec. 6, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL...
BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting PR Newswire BERGEN, Norway, Nov. 11, 2020 BERGEN, Norway , Nov. 11, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing...